Echinococcosis: How Parasitic Tapeworms Cause Hydatid Cysts

Echinococcosis is a parasitic disease caused by tapeworms in the genus Echinococcus, and it remains one of the most dangerous helminth infections a person can contract. The parasite forms cysts, sometimes the size of a grapefruit or larger, in internal organs, most commonly the liver and lungs. Globally, the disease caused roughly 148,500 new infections, more than 633,000 prevalent cases, and about 1,364 deaths in 2021 alone. What makes echinococcosis particularly insidious is that a person can carry growing cysts for years without any symptoms, only to face a serious surgical problem by the time the disease is finally discovered.

Two Diseases Under One Name

The term “echinococcosis” actually covers two very different illnesses caused by different species of the same tapeworm genus. Cystic echinococcosis, the more common form, is caused by Echinococcus granulosus and produces fluid-filled cysts that grow slowly, pushing aside surrounding tissue through pressure. Alveolar echinococcosis, caused by E. multilocularis, behaves far more aggressively. Its growth pattern resembles that of a malignant tumor, infiltrating throughout the liver, spreading into neighboring organs, and even forming distant metastasis-like lesions.¹ Pathologists can distinguish the two by examining the tissue under a microscope: cystic echinococcosis tends to produce fewer, larger cysts with thicker outer walls, while alveolar echinococcosis creates many tiny cysts with thin walls that branch out like an invasive network.²

The distinction matters enormously for patients. Cystic echinococcosis grows slowly and can often be managed or cured. Alveolar echinococcosis, left untreated, is almost always fatal, and even with treatment it requires years of medication and close surveillance. The two forms also occupy different geographic niches and involve different animals in their transmission cycles, so the risk factors for each depend heavily on where you live and what animals are around you.

How People Get Infected

The tapeworm’s life cycle runs between two types of animal hosts. Dogs (and other canids like wolves and foxes) serve as the definitive hosts, carrying the adult tapeworms in their intestines and shedding microscopic eggs in their feces. Herbivores such as sheep, cattle, and goats are intermediate hosts: they swallow the eggs while grazing on contaminated pasture, and the eggs develop into larval cysts in their organs. When a dog eats the organs of an infected animal, the cycle starts over.³ Humans are accidental dead-end hosts. We get infected the same way sheep do, by swallowing eggs shed in dog feces, but the parasite has no way to complete its cycle in us.

For alveolar echinococcosis, the cycle is similar but involves wild animals. Foxes are the main definitive hosts, and small rodents serve as intermediate hosts. People typically become infected through contact with fox feces or by handling contaminated soil, water, or foraged foods. The eggs themselves are remarkably hardy. Field experiments have shown they can survive outdoors for weeks to years, and they resist many environmental stresses, though they are somewhat vulnerable to drying out.⁴ Rain, wind, insects, and even birds help scatter the eggs across the landscape, contaminating water sources, soil, and produce.

A cross-climatic survey of farms in Iran tested vegetables, soil, and dog feces for E. granulosus DNA and found contamination on about a third of the farms sampled. Soil had the highest contamination rate at roughly 28%, followed by dog feces at about 16%, while vegetables showed the lowest rate at under 1%.⁵ Those numbers highlight why hand-washing and produce-washing matter in endemic areas, though the mere detection of eggs on a surface does not guarantee they are still viable and capable of causing infection.

How the Parasite Hides From Your Immune System

One reason echinococcosis can persist for so long in the body is that the parasite is remarkably good at manipulating the host’s immune response. The larval cyst releases molecules, particularly a protein called antigen B, that actively suppress the immune reactions that would normally destroy it. Antigen B blocks the recruitment of neutrophils, the immune cells that typically rush to the site of an infection as a first line of defense.⁶ At the same time, it steers the immune system’s T-helper cells toward a response that is largely ineffective against the parasite.⁷

In practical terms, the parasite tricks the body into mounting an allergic-type immune response rather than the kind of inflammatory response that would actually kill it. This immune misdirection promotes parasite survival and is strongest in patients whose disease is actively progressing.⁸ The result is a standoff that can last decades: the cyst grows slowly, the immune system keeps it somewhat contained but cannot eliminate it, and the patient remains unaware until the cyst gets large enough to press on something important or, worse, ruptures.

Symptoms and Where Cysts Show Up

Most people with cystic echinococcosis have no symptoms for years. Pulmonary cysts, for example, are frequently discovered by accident on a chest X-ray taken for some other reason. Symptoms typically appear only when a cyst grows large enough to produce a mass effect, compressing nearby structures. If a lung cyst ruptures, it can cause sudden coughing, chest pain, coughing up blood, or the dramatic expulsion of cyst fluid and membrane fragments.⁹ Rupture of a liver cyst can trigger severe allergic reactions, including life-threatening anaphylaxis, because the immune system suddenly encounters a flood of parasite antigens it has been kept away from.

While the liver and lungs are far and away the most common sites, hydatid cysts can develop almost anywhere in the body. Case reports document cysts in bone, heart, and brain, each presenting unique diagnostic and surgical challenges.¹⁰ Bone cysts are especially troublesome because bone tissue does not contain the cyst the way soft tissue does, allowing the parasite to erode through the bone structure. Brain cysts can mimic tumors or abscesses, and cardiac cysts carry the risk of rupture into the bloodstream. In areas where echinococcosis is common, clinicians need to keep the disease in mind whenever they encounter an unexplained cystic mass, no matter how unusual the location.

Diagnosis With Ultrasound and Blood Tests

Ultrasound is the workhorse of echinococcosis diagnosis, especially for liver cysts. It is cheap, portable, radiation-free, and can be used repeatedly to track how a cyst changes over time. The World Health Organization published a standardized ultrasound classification system for cystic echinococcosis that divides cysts into stages based on their appearance. Studies have confirmed that trained experts can reliably identify the characteristic signs using this system, making it a reproducible way to stage the disease.¹¹ Because it runs on battery power or a small generator, ultrasound can be taken into remote field settings to screen entire communities, something no other imaging technology can easily do.¹²

For alveolar echinococcosis, imaging often raises suspicion of liver cancer before the correct diagnosis is reached, because the infiltrative growth pattern closely mimics a malignant tumor on CT and MRI scans.¹³ Getting the species identification right matters because the treatment approach differs dramatically between the two forms.

Blood tests complement imaging but have important limitations. Serological tests such as ELISA and indirect hemagglutination detect antibodies against Echinococcus antigens, with ELISA achieving sensitivity around 85% and specificity near 89% in one comparative study.¹⁴ That means roughly one in six infected people may test negative, which is a real problem for screening. Standard blood tests also struggle to distinguish between the cystic and alveolar forms. Newer rapid immunochromatographic test kits have shown promise, differentiating alveolar from cystic echinococcosis with specificities of 99% and 100% respectively in one Chinese study population, though consistency with traditional ELISA-based tests was poor.¹⁵

An emerging approach involves detecting cell-free DNA from the parasite circulating in the patient’s blood. In at least one documented case, sequencing plasma cfDNA correctly identified alveolar echinococcosis in a patient who had initially been misdiagnosed with the cystic form.¹⁶ This technology is still in early stages, and the various techniques being explored range from next-generation sequencing to PCR-based methods.¹⁷ If it matures into a routine clinical tool, it could solve one of the hardest diagnostic problems in the field: telling the two forms apart before surgery.

Treatment Options

For cystic echinococcosis, treatment depends on the cyst’s stage, size, and location. The options break down into three broad categories:

Percutaneous drainage (PAIR): A needle is inserted through the skin under image guidance, and the cyst is punctured, aspirated, injected with a killing agent, and re-aspirated. A systematic review and meta-analysis found that percutaneous treatment produces recurrence rates comparable to open surgery, with fewer complications and shorter hospital stays.¹⁸ However, one comparative study noted that recurrence rates were somewhat higher in the PAIR group than in surgical groups, while the risk of biliary fistula was significantly lower.¹⁹
Surgery: Open or laparoscopic removal is still used for large cysts, cysts in complicated locations, or cases where PAIR is not feasible. Surgery carries more risk and a longer recovery but gives surgeons direct access to deal with complications like bile duct involvement.
Drug therapy: Albendazole is given alongside procedures and sometimes on its own for inoperable cases. It does not reliably kill established cysts by itself but can slow their growth and reduce the risk of recurrence after surgery or PAIR.

For alveolar echinococcosis, the picture is bleaker. Complete surgical removal of the parasitic mass, when possible, is the only chance of cure. Because the disease infiltrates tissues the way a cancer does, achieving clear margins is often difficult or impossible. When surgery cannot remove everything, patients need long-term, sometimes lifelong, drug treatment. Both albendazole and mebendazole are used, with an observational study reporting an overall success rate (disease stabilization without progression) of 97% over an average follow-up of about three years.²⁰ Albendazole is generally preferred because it costs less and is easier to take. Continuous rather than intermittent dosing has shown promising results in patients with progressive disease, though it is not formally licensed for continuous use in many countries.

Research into improved drug delivery is ongoing. Nanoparticle formulations combining albendazole with atovaquone have shown stronger parasite-killing effects in laboratory experiments than either drug alone in its standard form, potentially addressing the poor absorption that limits how much albendazole actually reaches the cyst.²¹

The Economic and Human Toll

Echinococcosis hits hardest in pastoral communities where people live in close contact with livestock and dogs. A 2021 global analysis found that younger and middle-aged adults bear the highest risk, and regions with lower socioeconomic development are disproportionately affected.²² The financial costs are staggering for a disease most people in wealthy countries have never heard of. When underreporting is accounted for, the global economic burden of cystic echinococcosis alone has been estimated at roughly $764 million annually, with over a million disability-adjusted life years lost.²³ That figure captures not just treatment costs but lost productivity, livestock losses, and the long-term disability suffered by patients who go undiagnosed for years.

Breaking the Cycle With Dog Deworming and Sheep Vaccines

Because the parasite cycles through dogs and livestock before reaching humans, the most effective prevention strategies target animals rather than people. Regular deworming of dogs with praziquantel kills the adult tapeworms and stops egg shedding. A field trial using slow-release praziquantel bars in dogs demonstrated dramatic results: the antibody-positive rate in local schoolchildren dropped from about 41% to just 5% over four years, while children in a control area without the intervention remained around 31% seropositive.²⁴

For alveolar echinococcosis, a ten-year dog deworming program in Tibetan communities in Sichuan Province, China, reduced human disease prevalence from about 6.3% to 3.7%. The program was effective in reducing infection in owned dogs, but it did not significantly impact infection in wildlife intermediate hosts like rodents and foxes, highlighting a key limitation.²⁵ Where wildlife reservoirs maintain the cycle independently of domestic animals, deworming dogs can reduce human cases but cannot eliminate the parasite from the environment.

On the livestock side, a recombinant vaccine called EG95 has been developed for sheep. In experimental trials, vaccination achieved protection levels above 94%, with both purified and non-purified versions of the antigen performing well. All unvaccinated control animals developed large numbers of viable cysts after being challenged with parasite eggs.²⁶ The vaccine produces a strong, long-lasting antibody response and can even be combined with standard clostridial vaccines that sheep already receive, simplifying adoption by farmers.²⁷ By preventing cyst formation in sheep, the vaccine breaks the transmission cycle at its most critical point: an uninfected sheep means no infected organs for dogs to eat, which means no new eggs shed into the environment. Wider uptake of both livestock vaccination and dog deworming together represents the most promising strategy for driving down human cases in endemic regions.²⁸

Urban Foxes and a Growing Risk in Europe

Alveolar echinococcosis was historically a disease of remote rural areas, but the expansion of red fox populations into European cities has changed the risk map. A study in and around Nancy, France, found that fox infection rates with E. multilocularis followed a steep gradient: about 54% of foxes in rural areas were infected, compared with roughly 31% in peri-urban zones and just 4% in the urban core.²⁹ The gradient tracked with diet: foxes eating more voles and water voles, which serve as intermediate hosts, carried heavier worm burdens, while foxes relying more on human food scraps were less likely to be infected. The infection has not disappeared at the city’s edge, though. A 4% prevalence among urban foxes still means contaminated feces in parks, gardens, and green spaces where people and pets spend time. For residents in endemic parts of Europe, this means that growing and foraging vegetables, gardening without gloves, or letting dogs roll in fox feces all carry a small but real risk.

Polycystic Echinococcosis in the Amazon

A third form of the disease, polycystic echinococcosis, exists in the Neotropics and is caused by Echinococcus vogeli. Its life cycle runs through bush dogs as definitive hosts and lowland pacas, a large rodent, as intermediate hosts.³⁰ People become infected when they hunt pacas and handle the animals’ viscera without proper precautions. In two villages in the Peruvian Amazon, nearly 12% of wild pacas examined were found to be infected, suggesting meaningful risk for local communities where paca meat is a regular food source.³¹

Despite being treatable, polycystic echinococcosis reaches a case fatality rate of around 29%, almost entirely because of late or missed diagnosis in remote Amazonian communities with limited healthcare access.³² Climate modeling suggests that transmission hotspots are concentrated in specific ecological zones across the Amazon basin, meaning that targeted surveillance in those areas could catch cases earlier and save lives. This form of echinococcosis remains deeply neglected, receiving a fraction of the research attention given to its cystic and alveolar cousins.

The Parasite’s Deep Evolutionary Roots

Genetic studies of Echinococcus populations around the world have revealed that these parasites have been evolving alongside their hosts for a very long time. Analysis of E. granulosus isolates from Xinjiang, in northwestern China, identified ancient lineages that predate strains found in France, Argentina, and Australia, suggesting that Central Asia may have been an important ancestral homeland for the sheep-dog strain.³³ For E. multilocularis, genetic analysis shows that European and Asian populations are distinct sister groups, and the level of genetic differentiation between continental populations suggests they have been separated since the Pleistocene, likely surviving in separate glacial refugia and being maintained by local wild canid and rodent hosts ever since.³⁴ Some North American haplotypes cluster with European rather than Asian strains, hinting at complex historical migration routes that may trace back to land bridges and ancient animal movements. Understanding this genetic architecture is not merely academic curiosity: it matters for vaccine development, because a vaccine designed against one genotype may not work equally well against strains circulating on another continent.